Mark R. Lackner

8.2k citations

84 papers · 4.5k · h-index 33

Impact in

Aging top 0.5%
- Genetics, Aging, and Longevity in Model Organisms
Cancer Research top 1%
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation

Papers in

Molecular Biology 38
- PI3K/AKT/mTOR signaling in cancer 16
- Epigenetics and DNA Methylation 6
Cancer Research 25
- Cancer Genomics and Diagnostics 20
- Breast Cancer Treatment Studies 4

Co-authors: Lukas C. Amler (23 shared papers)Carol O’Brien (21 shared papers)Jill M. Spoerke (28 shared papers)Stuart K. Kim (2 shared papers)Garret M. Hampton (22 shared papers)Elizabeth A. Punnoose (8 shared papers)Heidi Savage (12 shared papers)Timothy R. Wilson (14 shared papers)
Journals: Cancer Research (21 papers)Clinical Cancer Research (12 papers)Journal of Clinical Oncology (7 papers)Molecular Cancer Therapeutics (6 papers)PLoS ONE (3 papers)
Partner nations: United States France United Kingdom

In The Last Decade

Mark R. Lackner

81 papers receiving 4.4k citations

Peers

Countries citing papers authored by Mark R. Lackner

Since Specialization

Citations

This map shows the geographic impact of Mark R. Lackner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Lackner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Lackner more than expected).

Fields of papers citing papers by Mark R. Lackner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Lackner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Lackner. The network helps show where Mark R. Lackner may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark R. Lackner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark R. Lackner Line = papers co-authored together Mark R. Lackner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 84 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Clinical Cancer Research ·Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd, Guy Cavet, Steve Guerrero, Kenneth Jung, Tom Januario, Heidi Savage, Elizabeth A. Punnoose, Tom Truong, Wei Zhou, Leanne Berry, Lesley Murray, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner	2009	386
2	Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib Clinical Cancer Research ·Elizabeth A. Punnoose, Siminder Atwal, Weiqun Liu, Rajiv Raja, Bernard M. Fine, Brett Hughes, Rodney J. Hicks, Garret M. Hampton, Lukas C. Amler, Andrea Pirzkall, Mark R. Lackner	2012	343
3	TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer Science Signaling ·Susanna Stinson, Mark R. Lackner, Alex Adai, Nancy Yu, Hyo‐Jin Kim, Carol O’Brien, Jill M. Spoerke, Suchit Jhunjhunwala, Zachary Boyd, Thomas Januario, Robert Newman, Yue Peng, Richard Bourgon, Zora Modrušan, Howard M. Stern, Søren Warming, Frédéric J. de Sauvage, Lukas C. Amler, Ru‐Fang Yeh, David Dornan	2011	253
4	Molecular Biomarker Analyses Using Circulating Tumor Cells PLoS ONE ·Elizabeth A. Punnoose, Siminder Atwal, Jill M. Spoerke, Heidi Savage, Ajay Pandita, Ru‐Fang Yeh, Andrea Pirzkall, Bernard M. Fine, Lukas C. Amler, Daniel S. Chen, Mark R. Lackner	2010	239
5	Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant Nature Communications ·Jill M. Spoerke, Steven Gendreau, Kimberly Walter, Jiaheng Qiu, Timothy R. Wilson, Heidi Savage, Junko Aimi, Mika K. Derynck, Meng Chen, Iris T. Chan, Lukas C. Amler, Garret M. Hampton, Stephen Johnston, Ian E. Krop, Peter Schmid, Mark R. Lackner	2016	223
6	Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models Clinical Cancer Research ·Carol O’Brien, Jeffrey J. Wallin, Deepak Sampath, Debraj GuhaThakurta, Heidi Savage, Elizabeth A. Punnoose, Jane Guan, Leanne Berry, Wei Wei Prior, Lukas C. Amler, Marcia Belvin, Lori S. Friedman, Mark R. Lackner	2010	201
7	A MAP kinase homolog, mpk-1, is involved in ras-mediated induction of vulval cell fates in Caenorhabditis elegans. Genes & Development ·Mark R. Lackner, Kerry Kornfeld, Leilani M Miller, H. Robert Horvitz, S K Kim	1994	182
8	Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes Molecular Cancer Research ·Xiaolan Hu, Howard M. Stern, Lin Ge, Carol O’Brien, Lauren E. Haydu, Cynthia D. Honchell, Peter M. Haverty, Brock A. Peters, Thomas D. Wu, Lukas C. Amler, John Chant, David Stokoe, Mark R. Lackner, Guy Cavet	2009	177
9	MAP Kinase Signaling Specificity Mediated by the LIN-1 Ets/LIN-31 WH Transcription Factor Complex during C. elegans Vulval Induction Cell ·Patrick Tan, Mark R. Lackner, Stuart K. Kim	1998	171
10	ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors Molecular Cancer Therapeutics ·Georgia Hatzivassiliou, Bonnie Liu, Carol O’Brien, Jill M. Spoerke, Klaus P. Hoeflich, Peter M. Haverty, Robert Soriano, William F. Forrest, Sherry Heldens, Huifen Chen, Karen Toy, Connie Ha, Wei Zhou, Kyung Song, Lori S. Friedman, Lukas C. Amler, Garret M. Hampton, John G. Moffat, Marcia Belvin, Mark R. Lackner	2012	158
11	Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models Clinical Cancer Research ·Jill M. Spoerke, Carol O’Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K. Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath, Lori S. Friedman, Leanne Ross, Garret M. Hampton, Lukas C. Amler, David S. Shames, Mark R. Lackner	2012	151
12	Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression Cancer Research ·Klaus P. Hoeflich, Sylvia Herter, Janet Tien, Leo Lap-Yan Wong, Leanne Berry, Jocelyn Chan, Carol O’Brien, Zora Modrušan, Somasekar Seshagiri, Mark R. Lackner, Howard M. Stern, Edna F. Choo, Lesley Murray, Lori S. Friedman, Marcia Belvin	2009	144
13	Mechanisms of Acquired Resistance to Targeted Cancer Therapies Future Oncology ·Mark R. Lackner, Timothy R. Wilson, Jeff Settleman	2012	121
14	miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast CancerA presentation from the Keystone Symposium on Epithelial Plasticity and Epithelial to Mesenchymal Transition, Vancouver, Canada, 21 to 26 January 2011. This Presentation also complements the Science Signaling Research Article by Stinson et al. published 14 June 2011. Science Signaling ·Susanna Stinson, Mark R. Lackner, Alex Adai, Nancy Yu, Hyojin Kim, Carol O’Brien, Jill M. Spoerke, Suchit Jhunjhunwala, Zachary Boyd, Thomas Januario, Robert Newman, Yue Peng, Richard Bourgon, Zora Modrušan, Howard M. Stern, Søren Warming, Frédéric J. de Sauvage, Lukas C. Amler, Ru‐Fang Yeh, David Dornan	2011	119
15	Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy Clinical Cancer Research ·Jiping Zha, Mark R. Lackner	2010	112
16	Genetic Analysis of the Caenorhabditis elegans MAP Kinase Gene mpk-1 Genetics ·Mark R. Lackner, Stuart K. Kim	1998	102
17	Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Journal of Clinical Oncology ·Thomas Powles, Mark R. Lackner, Stéphane Oudard, Bernard Escudier, Christy Ralph, Janet E. Brown, Robert E. Hawkins, Daniel Castellano, Brian I. Rini, Michael Staehler, Alain Ravaud, (unknown), Bridget O’Keeffe, Yulei Wang, Shan Lu, Jill M. Spoerke, L Huw, Michelle Byrtek, Rui Zhu, Joseph A. Ware, Robert J. Motzer	2016	101
18	Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast Cancer Cancer Research ·Carol O’Brien, Guy Cavet, Ajay Pandita, Xiaolan Hu, Lauren E. Haydu, Sankar Mohan, Karen Toy, Celina Sanchez Rivers, Zora Modrušan, Lukas C. Amler, Mark R. Lackner	2008	89
19	Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer Clinical Cancer Research ·Lisa Ryner, Yinghui Guan, Ron Firestein, Yuanyuan Xiao, Younjeong Choi, Christina Rabe, Shan Lu, Eloisa Fuentes, Ling‐Yuh Huw, Mark R. Lackner, Ling Fu, Lukas C. Amler, Carlos Bais, Yulei Wang	2015	87
20	Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Molecular Cancer Therapeutics ·Jiping Zha, Carol O’Brien, Heidi Savage, Ling‐Yuh Huw, Fiona Zhong, Leanne Berry, Gail D. Lewis Phillips, Elizabeth Luis, Guy Cavet, Xiaolan Hu, Lukas C. Amler, Mark R. Lackner	2009	66

About Mark R. Lackner

Mark R. Lackner is a scholar working on Molecular Biology, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 84 papers that have together received 4.5k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (20 papers), PI3K/AKT/mTOR signaling in cancer (16 papers), Lung Cancer Treatments and Mutations (8 papers), Cancer Cells and Metastasis (7 papers), Epigenetics and DNA Methylation (6 papers), Advanced Breast Cancer Therapies (6 papers), Breast Cancer Treatment Studies (4 papers) and HER2/EGFR in Cancer Research (4 papers). The work is most often cited by research in Aging (362 citations), Cancer Research (1.3k citations), Oncology (1.5k citations), Molecular Biology (2.3k citations) and Pulmonary and Respiratory Medicine (805 citations). Mark R. Lackner has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Lukas C. Amler, Carol O’Brien, Jill M. Spoerke, Stuart K. Kim, Garret M. Hampton, Elizabeth A. Punnoose, Heidi Savage, Timothy R. Wilson, Lori S. Friedman and Jiping Zha. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology, Molecular Cancer Therapeutics and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark R. Lackner

Impact in

Papers in i

In The Last Decade

Mark R. Lackner

Peers

Countries citing papers authored by Mark R. Lackner

Fields of papers citing papers by Mark R. Lackner

All Works

About Mark R. Lackner

Explore authors with similar magnitude of impact

Papers in